Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived multi-antigen-specific T cells
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived multi-antigen-specific T cells is an investigational adoptive cell therapy developed by Leiden University Medical Center (LUMC). The therapy utilizes MHC I-Streptamer (reversible HLA multimer) technology to simultaneously isolate multiple populations of donor-derived CD8-positive T cells specific for viral antigens (cytomegalovirus, Epstein-Barr virus, and adenovirus), tumor-associated antigens (TAA), and minor histocompatibility antigens (MiHA). This GMP-compliant procedure allows for the prophylactic infusion of these T cells approximately 6–8 weeks after T-cell-depleted allogeneic stem cell transplantation. The primary goal is to provide broad-spectrum immunity to prevent both viral infections and disease relapse in patients with hematological malignancies, such as leukemia.
- Other names
- Streptamer-selected multi-antigen-specific T cellsmulti-antigen-specific T cells
02
Targets
TAA-HLA-A*02 (Tumor-associated antigen peptide-HLA-A*02 complex)pMHC (Peptide-MHC complex family)pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)Minor histocompatibility antigen peptide-HLA complexesHAdV (Human adenovirus)
Beyond the preview
Go deeper on donor-derived multi-antigen-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived multi-antigen-specific T cells.